Grifols is leading or participating in more than 25 initiatives researching potential treatment options for different COVID-19 disease stages, including several clinical trials with plasma-derived medicines and convalescent plasma.

1. Anti-SARS-CoV-2 Hyperimmune Globulin

Grifols is currently investigating an anti-SARS-CoV-2 hyperimmune globulin for its potential to provide neutralizing antibodies against the SARS-CoV-2 virus. It's an immunoglobulin containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.

The first international multicenter clinical trial evaluating its safety, efficacy and tolerability as a potential treatment for COVID-19 hospitalized patients started in October 2020.

The phase 3 trial, known as Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC), is randomized, double-blind, placebo-controlled and adaptive and will include 500 hospitalized adults with COVID-19 in up to 58 hospitals covering 18 countries, including the United States and Spain.

Researchers will determine if giving the anti-SARS-CoV-2 hyperimmune globulin intravenously when COVID-19 symptoms first appear can augment the natural antibody response to SARS-CoV-2, thereby reducing the risk of more serious illness and death.

This trial is part of a collaboration with U.S. government agencies such as the Food and Drug Administration (FDA) and the Biomedical Advanced Research Development Authority (BARDA). It is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).

Another clinical trial will start in February in Spain in collaboration with the researchers Oriol Mitjà and Bonaventura Clotet from Germans Trias i Pujol Hospital in Badalona (Barcelona). It will include 800 asymptomatic SARS-CoV-2-positive patients who will receive the immunoglobulin subcutaneously on an outpatient basis. The treatment would provide immediate protection after exposure to the virus and could be used to complement the vaccine in the early phase after vaccination.

The anti-SARS-CoV-2 hyperimmune globulin is manufactured at our facilities in Clayton, North Carolina, especially equipped for the production of plasma-derived medicines for infectious diseases. Grifols collects convalescent plasma through its industry-leading network of plasma-collection centers in the U.S. and Germany, as well as through a collaboration with blood banks in Spain.

Moving decisively against

Grifols has over 100 years of extensive experience in the research, development and successful application of plasma-derived therapies, including hyperimmune globulins for the prevention and treatment of well-known diseases such as rabies and tetanus.

Anti-SARS-CoV-2 Hyperimmune Globulin

A medicine based on plasma from recovered COVID-19 donors is being investigated as a potential treatment for COVID-19. 

2. Convalescent Plasma for Direct Transfusion

Grifols is currently conducting several clinical trials in Spain and the U.S. with convalescent plasma from recovered COVID-19 donors for direct transfusion. The trials are in collaboration with health regulatory agencies, selected blood banks, transfusion centers and public hospitals.

The studies will evaluate the safety and efficacy of convalescent plasma in reducing viral loads, inflammation and respiratory distress in COVID-19 hospitalized patients requiring intensive care.

Convalescent plasma was approved for emergency use by the FDA on August 23, 2020, to treat hospitalized patients with COVID-19.

Methylene blue inactivation

Direct transfusion of convalescent plasma to COVID-19 patients is being investigated as a potential treatment for the disease. Before transfusion, the convalescent plasma is pathogen-inactivated with methylene blue technology to help ensure to increase its safety.

3. Existing Plasma-derived Medicines: Alpha-1 antitrypsin, Immunoglobulins and Antithrombin III

Grifols is currently collaborating with different experts, academics, hospitals and researchers across the U.S. and Europe in several clinical trials to determine if plasma-derived medicines already used for other medical conditions can also treat patients with COVID-19.

These products include alpha-1 antitrypsin, immunoglobulins and antithrombin III, whose efficacy in reducing inflammation and respiratory distress is being evaluated in hospitalized patients with different disease progression, including those requiring intensive care.

Everything starts with donations

If you have recovered from COVID-19 and would like to donate plasma and help fight the pandemic, please consider giving your plasma at a donation center or blood bank near you.

Now more than ever, we are extremely grateful to those who donate.

Donate in U.S.

If you want to be a donor and you live in the U.S. go to Grifols Plasma

Donate in Germany

If you want to be a donor and you live in Germany, go to Haema

Donate in Spain

If you want to be a donor and you live in Spain, go to BST

Grifols is proud to be part of a coalition of world-class medical and research institutions, blood centers, life-science companies, philanthropic organizations and COVID-19 survivor groups that has come together to mobilize tens of thousands of people in the United States who have recovered from COVID-19 to donate their plasma, which contains essential antibodies that have fought off the disease and could help others do the same.



Go to TheFightIsInUs.org


From donors to patients

What makes Grifols unique is that people, from donors to patients, are at the heart of everything we do.

Read more

What is plasma?

Human plasma is the liquid part of blood. It contains critical proteins responsible for important life functions.

Read more

What is plasmapheresis?

A specialized procedure to collect plasma in which machines separate plasma from whole blood and return the blood cells to the donor.

Read more